In this issue:
Financial incentives for linkage to care and viral suppression
Long-acting cabotegravir injections in HIV-uninfected men
Durability of viral suppression with first-line ART
New-onset diabetes in HIV-treated adults
Fostemsavir in antiretroviralexperienced subjects
Gray and white matter abnormalities in treated HIV
Second-generation HIV-1 maturation inhibitor
Virologic outcomes in early ART
Switching from FTC/TAF to FTC/TDF via a third agent
TDF-based ART in HIV-infected pregnant women and their infants
Please login below to download this issue (PDF)